Immunic (IMUX) Stock: Buy, Sell, or Hold?
IMUX - Immunic, Inc. Common Stock
$11.42
-0.42 (-3.55%)
▼
5d:
-10.5%
30d:
-28.31%
90d:
-12.62%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When IMUX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IMUX is down 10.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IMUX is down 10.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IMUX is currently trading at $11.42, which is considered oversold relative to its 30-day fair value range of $13.29 to $16.54.
Technical Outlook: Technically, IMUX is in a uptrend. The price is currently testing key support at $11.24. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: IMUX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $43.09 (+277.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMUX is in a uptrend. The price is currently testing key support at $11.24. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: IMUX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $43.09 (+277.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$13.29 -
$16.54
Company Quality Score
48/100
(HOLD)
Options IV Signal
46th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
56.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 46th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 277.3% below Wall St target ($43.09)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.29 -
$16.54
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.34
(20.5%)
Support & Resistance Levels
Support Level
$11.24
Resistance Level
$16.30
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.71
Wall Street Target
$43.09
(+277.3%)
Share & Embed Analysis
Last updated: September 13, 2026 12:24 PM ET
Data refreshes hourly during market hours. Next update: 1:24 PM
Data refreshes hourly during market hours. Next update: 1:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMUX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 50 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$106 | 41 HOLD |
